Taylor Blackburn

Taylor Blackburn

MS in Regulatory Science, Degree Candidate, Johns Hopkins University
在 jhu.edu 的电子邮件经过验证
被引用次数：15864
clinical trials pharmaceutical development regulatory affairs FDA drug discovery
Erick H Turner

Erick H Turner

Professor, Department of Psychiatry, Oregon Health & Science University
在 ohsu.edu 的电子邮件经过验证
被引用次数：13078
publication bias research transparency FDA
Jennifer E. Miller

Jennifer E. Miller

NYU School of Medicine
在 nyumc.org 的电子邮件经过验证
被引用次数：7365
bioethics pharmaceutical industry regulation FDA
Rahul Mittal

Rahul Mittal

University of Miami
被引用次数：6322
Diabetes Endocrinology Regulatory Affairs FDA IRB
Christopher Mullin

Christopher Mullin

NAMSA, The Integra Group, University of Minnesota
在 namsa.com 的电子邮件经过验证
被引用次数：5309
clinical trials medical devices FDA cardiovascular disease
Joshua D Wallach

Joshua D Wallach

Assistant Professor, Rollins School of Public Health
在 emory.edu 的电子邮件经过验证
被引用次数：3196
Meta-research research methods research integrity FDA regulatory science
Manoj Hastak

Manoj Hastak

Professor of Marketing, American University
在 american.edu 的电子邮件经过验证
被引用次数：2708
Consumer Information Processing Deceptive Advertising Consumer Protection FTC FDA
Jongho "Philip" Won

Jongho "Philip" Won

Alston & Bird, LLP
在 alston.com 的电子邮件经过验证
被引用次数：1959
FDA medical device hearing aid cochlear implant hearing science
Genevieve P Kanter

Genevieve P Kanter

Associate Professor of Public Policy, University of Southern California
在 usc.edu 的电子邮件经过验证
被引用次数：1834
biomedical technologies FDA conflicts of interest payment models health economics
Sandra Casak

Sandra Casak

Hematologist and Oncologist
被引用次数：1449
Pediatrics Oncology rituximab ramucirumab FDA
1 - 10